Renee Aguiar-Lucander, a professional investor, has become chief executive officer of Pharmalink AB, a Swedish specialty pharmaceutical developer. Ms Aguiar-Lucander will be responsible for raising capital for the Phase 3 development of the company’s product for IgA nephropathy. Prior to joining Pharmalink, she was partner and chief operating officer of Omega Fund Management and before that, a partner of 3i Group Plc.
Ms Aguiar-Lucander holds a bachelor’s degree in finance from the Stockholm School of Economics in Sweden and an MBA from the INSEAD business school in France.
Pharmalink announced the appointment on 18 May 2017
Copyright 2017 Evernow Publishing Ltd